JP2011506274A - ファスチンを阻害するための方法 - Google Patents

ファスチンを阻害するための方法 Download PDF

Info

Publication number
JP2011506274A
JP2011506274A JP2010534970A JP2010534970A JP2011506274A JP 2011506274 A JP2011506274 A JP 2011506274A JP 2010534970 A JP2010534970 A JP 2010534970A JP 2010534970 A JP2010534970 A JP 2010534970A JP 2011506274 A JP2011506274 A JP 2011506274A
Authority
JP
Japan
Prior art keywords
fastin
cancer
actin
inhibitor
thr318
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010534970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506274A5 (enExample
Inventor
シン−ユン ファン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2011506274A publication Critical patent/JP2011506274A/ja
Publication of JP2011506274A5 publication Critical patent/JP2011506274A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
JP2010534970A 2007-11-21 2008-11-21 ファスチンを阻害するための方法 Withdrawn JP2011506274A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98960907P 2007-11-21 2007-11-21
PCT/US2008/012988 WO2009070244A2 (en) 2007-11-21 2008-11-21 Methods for inhibiting fascin

Publications (2)

Publication Number Publication Date
JP2011506274A true JP2011506274A (ja) 2011-03-03
JP2011506274A5 JP2011506274A5 (enExample) 2012-11-29

Family

ID=40679192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534970A Withdrawn JP2011506274A (ja) 2007-11-21 2008-11-21 ファスチンを阻害するための方法

Country Status (6)

Country Link
US (2) US20100297109A1 (enExample)
EP (1) EP2222343A4 (enExample)
JP (1) JP2011506274A (enExample)
CN (1) CN101918036A (enExample)
CA (1) CA2707009A1 (enExample)
WO (1) WO2009070244A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719671B2 (ja) 2003-03-28 2011-07-06 コーネル・リサーチ・ファンデーション・インコーポレイテッド ミグラスタチンアナログ組成物およびその使用
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
JP5744560B2 (ja) * 2011-02-21 2015-07-08 シーシーアイ株式会社 ファスシン（Ｆａｓｃｉｎ）遺伝子の働きを抑える短鎖ＲＮＡを含有する癌の予防、治療剤
AU2012239977B9 (en) 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
WO2015127125A1 (en) 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
CA3048497A1 (en) * 2017-02-24 2018-08-30 Flagship Pioneering Innovations V, Inc. Compositions and related methods for modulating endosymbionts
CN107446949A (zh) * 2017-07-25 2017-12-08 国家纳米科学中心 Pls3重组蛋白真核表达质粒及其构建方法和应用
JP2021504344A (ja) * 2017-11-22 2021-02-15 コーネル ユニヴァーシティー 転移阻害剤を含む共同治療法
CN112080499A (zh) * 2020-08-12 2020-12-15 南京医科大学 一种降低fascin-1基因表达的siRNA及其应用
GB202012761D0 (en) * 2020-08-14 2020-09-30 Univ Oxford Brookes Metastatis treatment or prevention
CN111944812A (zh) * 2020-08-17 2020-11-17 南通大学 靶向Fascin基因的siRNA分子及其应用
CN112243955B (zh) * 2020-10-23 2022-09-30 中国医学科学院北京协和医院 新型pls3基因敲除大鼠动物模型的构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
US8957056B2 (en) * 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8178505B2 (en) * 2005-01-05 2012-05-15 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
US7829066B2 (en) * 2006-12-27 2010-11-09 Memorial Sloan-Kettering Cancer Center Assay for anti-metastatic agents

Also Published As

Publication number Publication date
EP2222343A2 (en) 2010-09-01
CA2707009A1 (en) 2009-06-04
CN101918036A (zh) 2010-12-15
WO2009070244A3 (en) 2009-11-05
US20130259857A1 (en) 2013-10-03
WO2009070244A2 (en) 2009-06-04
US20100297109A1 (en) 2010-11-25
EP2222343A4 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
US20130259857A1 (en) Methods for inhibiting fascin
KR102130281B1 (ko) 감마 세크레타제 억제제를 포함하는 인간거대세포바이러스 감염 질환 예방 또는 치료용 약학적 조성물, 및 감마 세크레타제를 이용한 인간거대세포바이러스 감염 질환 치료제의 스크리닝 방법
JP5422204B2 (ja) ＤＧＫα阻害剤を含有する抗癌剤
Yuan et al. TIPE3 is a regulator of cell apoptosis in glioblastoma
JP2025127483A (ja) Ｒａｓ変異体癌を治療するための組成物および方法
JP2016538289A (ja) マクロファージ活性化の主要制御因子としてのｐａｒｐ９およびｐａｒｐ１４
EP3532494A2 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
Li et al. Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation
US8207139B2 (en) Function of GPR4 in vascular inflammatory response to acidosis and related methods
WO2005018675A1 (ja) 自己免疫疾患治療剤
US8580758B2 (en) Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
JP5246776B2 (ja) 急性骨髄性白血病治療剤の候補物質を同定する方法
US20240263175A1 (en) Composition for treating metastatic solid cancer, comprising tsg6 inhibitor
JP7138973B2 (ja) 腫瘍転移の薬物治療における標的、及びその使用
US20050265997A1 (en) Cancer treatment method by inhibiting MAGE gene expression or function
JP6018068B2 (ja) 細胞の増殖抑制方法、ｎｅｋ１０バリアント遺伝子に対するｒｎａ干渉作用を有する核酸分子、及び抗癌剤
Lewis Characterizing Glioblastoma Multiforme by Linking Molecular Profiles to Macro Phenotypes
US20190336579A1 (en) Compositions and methods to induce targeted apoptosis by modulating protein tyrosine phosphatase 13 (ptpn13)
KR102026142B1 (ko) Crif1 억제제를 함유하는 항암 및 암전이 억제용 조성물
US20050208058A1 (en) Compositions and methods for modulating cell division
JP5382746B2 (ja) 抗癌剤耐性を獲得した癌細胞の抗癌剤感受性を回復する方法
US20110044991A1 (en) Methods and compositions for treating lymphoma and myeloma
WO2014095916A1 (en) Ninjurin-1 as therapeutic target for brain tumor
KR20210114661A (ko) VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법
Verma et al. Characterization of RACK7 as a Novel Factor Involved in BRCA1 Mutation Mediated Breast Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121002

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130124